The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

Size: px
Start display at page:

Download "The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009"

Transcription

1 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

2 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain the rationale and major findings of the JUPITER trial 3. Understand the practical applicability of the JUPITER trial and role of hs-crp testing in clinical practice

3 Statins Lower LDL-C C = Lower CAD Risk 4S-Pl 25 Rx - Drug group Pl - Placebo group Percent with CHD event S-Rx LIPID-Pl CARE-Pl HPS-Pl CARE-Rx LIPID-Rx HPS-Rx TNT-A10 TNT-A80 0 End of study LDL-C mmol/l Adapted from Kastelein JJ. Atherosclerosis 1999;143(Suppl 1):S17 S21. Heart Protection Study Collaborative Group. Lancet 2002;360:7 22

4 TNT: Stroke (Fatal or Nonfatal) Proportion of patients experiencing fatal or nonfatal stroke HR = 0.75 (95%CI 0.59, 0.96) P=0.02 Atorvastatin 10 mg Atorvastatin 80 mg Relative risk reduction = 25% Time (years) LaRosa JC, et al. N Eng J Med. 2005;352

5 Heart Protection Study (HPS): Major Vascular Events VASCULAR EVENT SIMVASTATIN PLACEBO EVENT RATE RATIO (95% CI) (n = 10,269) (n = 10,267) Major coronary 8.7% 11.8% 27% RRR* (21-33%) Any stroke 4.3% 5.7% 25% RRR* (15-34%) Any revascularizations 9.1% 11.7% 24% RRR* (17-30%) ANY OF ABOVE 19.8% 25.2% 24% RRR* (19-28%) *p < STATIN better PLACEBO better Heart Protection Study Collaborative Group. Lancet. 2002;360:7-22.

6

7 Fatal or Non-fatal Stroke 16% Placebo Atorvastatin 16% RRR Fatal or Non-fatal Stroke (%) 12% 8% 4% NNT=46 Adjusted HR (95% CI)=0.84 (0.71, 0.99), p=0.03 0% Years Since Randomization Despite the significant risk reduction in the primary endpoint with atorvastatin 80 mg, there was a small but significant increase in hemorrhagic stroke with atorvastatin 80 mg vs. placebo (0.9% absolute risk reduction, p-value 0.02) The SPARCL Investigators. N Engl J Med Aug 10;355(6):

8

9 Prevalence of conventional risk factors in male patients with CHD Three 8.9% Four (0.9%) 19.4% None Two 27.8% 43.0% One Total male patients= CHD=coronary heart disease smoking, hypertension, hypercholesterolaemia and diabetes mellitus Khot UN et al. JAMA 2003; 290:

10 AFCAPS/TexCAPS TexCAPS: baseline LDL-C C and hscrp Study group Rate of cardiovascular events NNT Lovastatin Placebo Low LDL-C/low hscrp N/A Low LDL-C/high hscrp High LDL-C/low hscrp High LDL-C/high hscrp Median LDL-C=3.9 mmol/l (149 mg/dl). Median hscrp=1.6 mg/l AFCAPS/TexCAPS=Air Force/Texas Coronary Atherosclerosis Prevention Study; hscrp=high-sensitivity C-reactive protein; LDL-C=low-density lipoprotein cholesterol; N/A=not applicable; NNT=number needed to treat to prevent one coronary event Ridker PM et al. N Engl J Med 2001; 344:

11 Incidence of Recurrent MI or CHD Death according to Achieved Levels of Both LDL-C C and CRP: PROVE IT TIMI TIMI 22 Recurrent MI or Coronary Death (%) Follow-up (Years) Ridker PM et al. N Engl J Med 2005;352: LDL 70 mg/dl, CRP 2 mg/l LDL 70 mg/dl, CRP <2 mg/l LDL <70 mg/dl, CRP 2 mg/l LDL <70 mg/dl, CRP <2 mg/l Slide Source LipidsOnline

12 Objective Low LDL-C (<3.36 mmol/l, TG <5.65 mmol/l) Elevated CRP levels (CRP levels 2.0 mg/l) Men aged 50 years; women aged 60 years Does long-term treatment with rosuvastatin 20 mg daily decrease the rate of first major cardiovascular events compared with placebo? Ridker PM. Circulation 2003; 108: Ridker PM. Am J Cardiol 2007; 100:

13 JUPITER - Patient Flow 89,890 subjects screened 17,802 randomised Rosuvastatin 20mg n=8,901 Placebo n=8,901 Lost to follow up n=44 Lost to follow up n=37 Completed study n=8,857 Completed study n=8,864 Ridker P et al. N Eng J Med 2008;359:

14 JUPITER study design N=17,802 Placebo run-in Rosuvastatin 20 mg (n~8901) Placebo (n~8901) Visit: Week: month intervals Final 3 4 y Lead-in/ eligibility Randomisation Lipids CRP Tolerability Lipids CRP Tolerability Lipids CRP Tolerability HbA 1C CAD=coronary artery disease; LDL-C=low-density lipoprotein cholesterol; CRP=C-reactive protein; HbA 1c =glycated haemoglobin Ridker PM. Circulation 2003; 108: Ridker PM. Am J Cardiol 2007; 100:

15 JUPITER study endpoints Primary first occurrence of a major CV event (CV death, stroke, MI, unstable angina or arterial revascularisation) Secondary Efficacy (incident diabetes mellitus, venous thromboembolic events, bone fractures) Safety (total mortality non-cv mortality, adverse events)

16 Baseline characteristics Male, % Mean age, years Race, % White Mean BMI, kg/m 2 Mean blood pressure, mmhg Systolic/diastolic Current smoker, % Metabolic syndrome Randomised (n=17,802) / % BMI=body mass index Ridker PM et al. Am J Cardiol 2007; 100:

17 Laboratory parameters at baseline Total cholesterol LDL-C HDL-C Non-HDL-C Triglycerides Glucose hscrp (mg/l) HbA 1c (%) mmol/l Values expressed as median (interquartile range). For hscrp, values are the mean of the screening & randomisation visits. LDL-C=low-density lipoprotein cholesterol; HDL-C=high-density lipoprotein cholesterol; hscrp=median high sensitivity C- reactive protein; HbA 1c =glycosylated haemoglobin Ridker PM et al. Am J Cardiol 2007; 100:

18 JUPITER - Primary Endpoint Percent of patients with primary endpoint Hazard Ratio 0.56 (95% CI ) P< Placebo Years Number at risk Rosuvastatin Placebo Rosuvastatin 20 mg NNT for 2 yrs = 95 5 yrs* = 25 Ridker P et al. N Eng J Med 2008;359:

19

20

21

22

23 Tolerability and Safety Placebo Rosuvastatin P value [n=8901] [n=8901] Adverse Events, (%) Any serious adverse event Muscle weakness, stiffness, pain Myopathy Rhabdomyolysis 0.0 <0.1 * ---- Newly diagnosed cancer Death from cancer Gastrointestinal disorders Renal disorders Bleeding Hepatic disorders Other events, (%) Newly diagnosed diabetes ** Haemorrhagic stroke *Occurred after trial completion; **physician -reported Ridker P et al. N Eng J Med 2008;359:

24 Interpretation 44% RRR in primary endpoint, 20% RRR mortality in PRIMARY PREVENTION 1.9 years of median follow-up Absolute risk reduction is low because absolute risk was low Treatment well tolerated Hs-CRP to FURTHER RISK STRATIFY Magnitude of LDL red n = magnitude of benefit

25 Interpretation If someone you would already treat do NOT check hs-crp If someone you would not typically treat consider hs-crp to further risk stratify If hs-crp > 2 mg/l consider treat Consider false positives Go big or go home

26 Summary Ischemic stroke / TIA = high vascular risk Start statin therapy LDL < 2.0 AND >50% red n JUPITER identified previously unrecognized group at higher risk Hs-CRP only in those you re not sure if treat (intermediate risk, male > 50, female > 60) Go big or go home

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011

Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011 Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011 Disclosure of Conflicts of Interest I have received travel grants and honoraria from sanofi-aventis, Pfizer, Servier,

More information

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by

More information

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

How to Reduce Residual Risk in Primary Prevention

How to Reduce Residual Risk in Primary Prevention How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with

More information

Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10,061 39 Countries April 2011 - June 2017

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Is Lower Better for LDL or is there a Sweet Spot

Is Lower Better for LDL or is there a Sweet Spot Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,

More information

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. 2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality

More information

ATP IV: Predicting Guideline Updates

ATP IV: Predicting Guideline Updates Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations

More information

Landmark Clinical Trials.

Landmark Clinical Trials. Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug

More information

The TNT Trial Is It Time to Shift Our Goals in Clinical

The TNT Trial Is It Time to Shift Our Goals in Clinical The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia

More information

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy? Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists

More information

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi

More information

LDL cholesterol and cardiovascular outcomes?

LDL cholesterol and cardiovascular outcomes? LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary

More information

Is it an era for statin for life?

Is it an era for statin for life? Is it an era for statin for life? Mohamed Abdel Ghany Professor of Cardiology Cairo University Cardiovascular Disease (CVD) is the leading global cause of death 1 Dyslipidemia as a main Risk Factor for

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

Dyslipedemia New Guidelines

Dyslipedemia New Guidelines Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy

More information

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space? Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09

More information

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

Introduction. Objective. Critical Questions Addressed

Introduction. Objective. Critical Questions Addressed Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:

More information

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular

More information

CLINICAL OUTCOME Vs SURROGATE MARKER

CLINICAL OUTCOME Vs SURROGATE MARKER CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?

New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate

More information

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. 2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality

More information

Weigh the benefit of statin treatment: LDL & Beyond

Weigh the benefit of statin treatment: LDL & Beyond Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research

More information

Expert Meeting on Large Simple Trials (LST s)

Expert Meeting on Large Simple Trials (LST s) Expert Meeting on Large Simple Trials (LST s) Clinical Trials Transformation Initiative Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin JUPITER Johannes

More information

Dyslipidemia in women: Who should be treated and how?

Dyslipidemia in women: Who should be treated and how? Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European

More information

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20

More information

Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice

Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP

More information

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

Calculating RR, ARR, NNT

Calculating RR, ARR, NNT Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event

More information

In-Ho Chae. Seoul National University College of Medicine

In-Ho Chae. Seoul National University College of Medicine The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering

More information

CHOLESTEROL-LOWERING THERAPHY

CHOLESTEROL-LOWERING THERAPHY CHOLESTEROL-LOWERING THERAPHY TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 50,194 15,036 30.0% 60.8 3.2 1/ 6 (16.7%) HR

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were

More information

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu

More information

Preventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk

Preventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk PREVENTING CARDIOVASCULAR DISEASE WITH LIPID MANAGEMENT : MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict

More information

Changing lipid-lowering guidelines: whom to treat and how low to go

Changing lipid-lowering guidelines: whom to treat and how low to go European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,

More information

10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?

10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk? Lessons Learned from Tim Russert: Investigating Residual Risk Peter H. Jones, MD, FACP Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, Texas Tim Russert:

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular

More information

Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence

Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University

More information

Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus

Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus C. Noel Bairey Merz MD, FACC, FAHA Professor and Women s Guild Endowed Chair Director, Barbra Streisand Women

More information

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for + Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics

More information

REAL-CAD. : Cardiovascular benefit of pitavastatin in stable coronary artery disease

REAL-CAD. : Cardiovascular benefit of pitavastatin in stable coronary artery disease REAL-CAD : Cardiovascular benefit of pitavastatin in stable coronary artery disease Soo-Joong Kim M.D., PhD. Department of Cardiology, Internal Medicine, Kyung Hee University Hospital I have nothing to

More information

journal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract

journal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,

More information

Lipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:

Lipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of: Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public

More information

Cholesterol Treatment Update

Cholesterol Treatment Update Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:

More information

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Placebo-Controlled Statin Trials Prevention Of CVD in Women MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cholesterol Treatment Trialists Collaboration.

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

Lessons from Recent Atherosclerosis Trials

Lessons from Recent Atherosclerosis Trials Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD

More information

Lipid Panel Management Refresher Course for the Family Physician

Lipid Panel Management Refresher Course for the Family Physician Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new

More information

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t? Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC. Cardiovascular Center, Korea University Guro Hospital

Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC. Cardiovascular Center, Korea University Guro Hospital Novel Statin Strategy to Prevent Atherosclerotic Cardiovascular Disease in Diabetic Patients-Curtailing Heart Attack : Korean Data and JUPITER again in spotlight Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI,

More information

Methods. Background and Objectives STRADIVARIUS

Methods. Background and Objectives STRADIVARIUS STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau

More information

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor

More information

Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) New York City Cardiovascular Symposium December 10, 2017 Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Paul M Ridker, MD, MPH

More information

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD 2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:

More information

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised

More information

The Clinical Debates

The Clinical Debates The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

CVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure

CVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and

More information

Contemporary management of Dyslipidemia

Contemporary management of Dyslipidemia Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that

More information

Traitements associés chez l hypertendu: Statines, Aspirine

Traitements associés chez l hypertendu: Statines, Aspirine Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact

More information

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical

More information

Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)

Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA) Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular

More information

Pharmaceutical Help to Control Cholesterol

Pharmaceutical Help to Control Cholesterol Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon

More information

AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5)

AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5) AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5) Jacques Genest MD Cardiovascular Research Laboratory McGill University Health Center Disclosure J. Genest MD 2012 Advisory Board, Speaker s Bureau, Consultant,

More information

LDL and the Benefits of Statin Therapy

LDL and the Benefits of Statin Therapy LDL and the Benefits of Statin Therapy Allan Sniderman McGill University ACC/AHA did not recommend a target-based approach. Right? P 2899 The Expert Panel was unable to find any RCTs that evaluated titration

More information

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee

More information

JAMA. 2011;305(24): Nora A. Kalagi, MSc

JAMA. 2011;305(24): Nora A. Kalagi, MSc JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for

More information

Disclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?

Disclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now? Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl

More information

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li

More information

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III

More information

Should I use statins?

Should I use statins? I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of

More information

New Cholesterol Guidelines What the LDL are we supposed to do now?!

New Cholesterol Guidelines What the LDL are we supposed to do now?! New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013

More information

Environmental. Vascular / Tissue. Metabolics

Environmental. Vascular / Tissue. Metabolics Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood

More information

Welcome! Mark May 14, Sat!

Welcome! Mark May 14, Sat! Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,

More information

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Protecting the heart and kidney: implications from the SHARP trial

Protecting the heart and kidney: implications from the SHARP trial Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Cholesterol Management Roy Gandolfi, MD

Cholesterol Management Roy Gandolfi, MD Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians

More information

An example of a systematic review and meta-analysis

An example of a systematic review and meta-analysis An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy

More information

Lipid Management 2013 Statin Benefit Groups

Lipid Management 2013 Statin Benefit Groups Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date

More information

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System

More information

New Insights into the Biology of Atherosclerosis and Primary Prevention: Controversy and Consensus in the JUPITER Trial

New Insights into the Biology of Atherosclerosis and Primary Prevention: Controversy and Consensus in the JUPITER Trial Fundacion Fernandez-CruzXXVIII Leccion Memorial New Insights into the Biology of Atherosclerosis and Primary Prevention: Controversy and Consensus in the JUPITER Trial Paul M Ridker, MD, MPH Eugene Braunwald

More information

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Ronald M. Goldenberg, MD, FRCPC, FACE Consultant Endocrinologist, North York General Hospital Medical Co-Director, LMC Endocrinology

More information

How to Handle Statin Intolerance in the High Risk Patient

How to Handle Statin Intolerance in the High Risk Patient How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl

More information

Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP

Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Professor of Medicine Medical-Director, Preventive Cardiology John Ochsner Heart and Vascular

More information